Table 5. Demographics of recipient.
| Variables | Total | Period 1 | Period 2 | Period 3 | P value |
|---|---|---|---|---|---|
| Patients, n | 300 | 100 | 100 | 100 | – |
| Age, mean ± SD (year) | 54.6±10.9 | 53.0±10.2 | 54.5±10.8 | 56.3±11.5 | 0.10 |
| Gender (M:F) | 222:78 | 78:22 | 69:31 | 75:25 | 0.33 |
| BMI, mean ± SD (kg/m2) | 23.8±3.4 | 23.9±3.3 | 24.0±3.5 | 23.6±3.4 | 0.75 |
| Underlying liver disease, n (%) | 0.45 | ||||
| Hepatitis B | 181 (60.3) | 68 (68.0) | 56 (56.0) | 57 (57.0) | |
| Alcohol | 61 (20.3) | 16 (16.0) | 23 (23.0) | 22 (22.0) | |
| Hepatitis C | 15 (5.0) | 5 (5.0) | 5 (5.0) | 5 (5.0) | |
| NBNC liver cirrhosis | 8 (2.7) | 3 (3.0) | 4 (4.0) | 1 (1.0) | |
| Sclerosing cholangitis | 7 (2.3) | 2 (2.0) | 2 (2.0) | 3 (3.0) | |
| Autoimmune hepatitis | 5 (1.7) | 2 (2.0) | 3 (3.0) | 0 (0) | |
| NASH | 4 (1.3) | 0 (0) | 0 (0) | 4 (4.0) | |
| Overlap syndrome | 3 (1.0) | 0 (0) | 1 (1.0) | 2 (2.0) | |
| HBV + HCV | 3 (1.0) | 1 (1.0) | 2 (2.0) | 0 (0) | |
| Etc. | 13 (4.3) | 3 (3.0) | 4 (4.0) | 6 (6.0) | |
| Hepatocellular carcinoma, n (%) | 187 (62.3) | 71 (71.0) | 59 (59.0) | 57 (57.0) | 0.09 |
| MELD score, mean ± SD | 14.7±6.2 | 17.7±4.8 | 14.0±6.3 | 12.4±6.2 | <0.01 |
| ABO incompatibility, n (%) | 53 (17.7) | 15 (15.0) | 11 (11.0) | 27 (27.0) | 0.01 |
SD, standard deviation; BMI, body mass index; NASH, nonalcoholic steatohepatitis; HBV, hepatitis B virus; HCV, hepatitis C virus; MELD, model for end-stage liver disease score.